Compare Ascendis Pharma A/S (ASND) vs Iron Mountain Inc (IRM) Price & Performance

Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.

The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.

Iron Mountain (IRM) trades at $121.50, up 1.69% today, with strong recent earnings beats and a bullish analyst consensus of 65% buy ratings. The stock shows a bearish technical signal but is supported by positive momentum in data center demand and a recent $1.5 billion debt offering. Revenue growth is steady, though net margins are thin at 3.76%, and the company carries high debt levels with a debt-to-asset ratio of 74.39% as of 2024.

Outlook is mixed: robust data center growth and dividend yield offer upside, but high valuation (P/E 132.08) and leverage pose risks. The consensus price target of $138.67 suggests 14% potential upside, yet technical resistance near $122 may limit near-term gains. Investors should weigh strong institutional support against elevated financial risk.